GSK cuts outlook as weak lung drug sales and strong pound hit
- Written by Editor
- Published in News Feeds
LONDON (Reuters) - GlaxoSmithKline cut its 2014 outlook after sales fell by a worse-than-expected 13 percent in the second quarter as its all-important lung drugs struggled in the United States and a strong pound took a bite out of growth.